Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD

11.62  +0.03 (+0.26%)

After market: 11.5 -0.12 (-1.03%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to CRMD. CRMD was compared to 195 industry peers in the Pharmaceuticals industry. While CRMD has a great health rating, its profitability is only average at the moment. CRMD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make CRMD suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year CRMD was profitable.
CRMD had a negative operating cash flow in the past year.
In the past 5 years CRMD always reported negative net income.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of 11.49%, CRMD belongs to the top of the industry, outperforming 93.85% of the companies in the same industry.
CRMD has a Return On Equity of 14.95%. This is amongst the best in the industry. CRMD outperforms 89.74% of its industry peers.
The Return On Invested Capital of CRMD (9.93%) is better than 87.69% of its industry peers.
Industry RankSector Rank
ROA 11.49%
ROE 14.95%
ROIC 9.93%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin of CRMD (20.81%) is better than 94.36% of its industry peers.
With an excellent Operating Margin value of 17.53%, CRMD belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.
CRMD has a better Gross Margin (95.19%) than 97.44% of its industry peers.
CRMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.53%
PM (TTM) 20.81%
GM 95.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CRMD is still creating some value.
Compared to 1 year ago, CRMD has more shares outstanding
Compared to 5 years ago, CRMD has more shares outstanding
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CRMD has an Altman-Z score of 12.40. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.
CRMD's Altman-Z score of 12.40 is amongst the best of the industry. CRMD outperforms 88.21% of its industry peers.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.4
ROIC/WACC1.01
WACC9.8%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

CRMD has a Current Ratio of 4.21. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
CRMD has a Current ratio of 4.21. This is in the better half of the industry: CRMD outperforms 64.10% of its industry peers.
CRMD has a Quick Ratio of 3.99. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRMD (3.99) is better than 64.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 3.99
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 123.66% over the past year.
The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)123.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 53.20% on average over the next years. This is a very strong growth
CRMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.29% yearly.
EPS Next Y346.76%
EPS Next 2Y158.11%
EPS Next 3Y101.76%
EPS Next 5Y53.2%
Revenue Next Year264.58%
Revenue Next 2Y136.58%
Revenue Next 3Y90.53%
Revenue Next 5Y51.29%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

CRMD is valuated quite expensively with a Price/Earnings ratio of 52.82.
Compared to the rest of the industry, the Price/Earnings ratio of CRMD indicates a somewhat cheap valuation: CRMD is cheaper than 80.00% of the companies listed in the same industry.
CRMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.45.
CRMD is valuated cheaply with a Price/Forward Earnings ratio of 7.55.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 89.23% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CRMD to the average of the S&P500 Index (21.90), we can say CRMD is valued rather cheaply.
Industry RankSector Rank
PE 52.82
Fwd PE 7.55
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CRMD is valued a bit cheaper than the industry average as 78.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 46.86
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CRMD may justify a higher PE ratio.
CRMD's earnings are expected to grow with 101.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y158.11%
EPS Next 3Y101.76%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (7/3/2025, 7:14:05 PM)

After market: 11.5 -0.12 (-1.03%)

11.62

+0.03 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners36.74%
Inst Owner Change0.01%
Ins Owners1.19%
Ins Owner Change7.3%
Market Cap788.07M
Analysts83.33
Price Target16.73 (43.98%)
Short Float %12.81%
Short Ratio4.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.59%
Min EPS beat(2)13.12%
Max EPS beat(2)54.06%
EPS beat(4)4
Avg EPS beat(4)30.36%
Min EPS beat(4)1.96%
Max EPS beat(4)54.06%
EPS beat(8)6
Avg EPS beat(8)15.62%
EPS beat(12)8
Avg EPS beat(12)11.61%
EPS beat(16)11
Avg EPS beat(16)11.55%
Revenue beat(2)2
Avg Revenue beat(2)9.51%
Min Revenue beat(2)3.69%
Max Revenue beat(2)15.32%
Revenue beat(4)3
Avg Revenue beat(4)-7.54%
Min Revenue beat(4)-52.8%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.81%
PT rev (3m)1.23%
EPS NQ rev (1m)-3.9%
EPS NQ rev (3m)-16.1%
EPS NY rev (1m)0%
EPS NY rev (3m)38.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.28%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)10.95%
Valuation
Industry RankSector Rank
PE 52.82
Fwd PE 7.55
P/S 9.55
P/FCF N/A
P/OCF N/A
P/B 6.86
P/tB 6.97
EV/EBITDA 46.86
EPS(TTM)0.22
EY1.89%
EPS(NY)1.54
Fwd EY13.24%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS1.22
BVpS1.69
TBVpS1.67
PEG (NY)0.15
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.49%
ROE 14.95%
ROCE 12.56%
ROIC 9.93%
ROICexc 30.34%
ROICexgc 31.85%
OM 17.53%
PM (TTM) 20.81%
GM 95.19%
FCFM N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 14.36%
Cap/Sales 0.08%
Interest Coverage 395.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 3.99
Altman-Z 12.4
F-Score5
WACC9.8%
ROIC/WACC1.01
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220%
EPS Next Y346.76%
EPS Next 2Y158.11%
EPS Next 3Y101.76%
EPS Next 5Y53.2%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A
Revenue Next Year264.58%
Revenue Next 2Y136.58%
Revenue Next 3Y90.53%
Revenue Next 5Y51.29%
EBIT growth 1Y126.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year472.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.56%
OCF growth 3YN/A
OCF growth 5YN/A